Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - Get Free Report) shares traded up 1% on Monday . The stock traded as high as $1.95 and last traded at $1.93. 23,983 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 842,200 shares. The stock had previously closed at $1.91.
Ampliphi Biosciences Price Performance
The firm has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $1.90.
Ampliphi Biosciences Company Profile
(
Get Free Report)
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ampliphi Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ampliphi Biosciences wasn't on the list.
While Ampliphi Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
